November Review

Was my sigh of relief audible everywhere? I've been doing this long enough to know that markets are cyclical and that the point of maximum frustration is usually when things are likely to start improving. However, watching almost every...

Deep Fried Turkey

Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain biking with The Gestalt Haus Gang, ending up at a similarly-named (mountain) biker bar tipping...

Show Me The Money

As the stock market hits new highs on all the major indexes seemingly daily, it appears that the market has moved to a “risk on” scenario. This coming after a very tough August when things looked rather bleak. There...
OLDWICK, N.J., Nov. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2019. "The PRV-031 program continues to build...
Tailwinds' Take: While this is not unexpected, PRIME designation is still good news for PRVB. We believe that, based on the stock's trading over the last few days, that a low has been put in place for Provention and...
Greetings from Stresa Italy, a gorgeous town on the edge of Lake Maggiore. With great food, excellent wines and friendly people, Italy is always a great place to relax. This is especially true during times of market weakness, as...
Tailwinds' Take: this is a very high quality addition to the board and lends a ton of credence to their diabetes programs. OLDWICK, N.J., Sept. 26, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to...
OLDWICK, N.J., Sept. 24, 2019 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its regulatory strategy regarding PRV-031 (teplizumab) for the prevention or delay of clinical type...
I tend to be very much a buy and hold investor. I take positions, add to them as I gain confidence and generally let them ride. I do add to stocks on weakness and will trim some into strength....
Tailwinds' Take: PRVB finally ripped the bandaid off and raised this money. A couple key takeaways. The headline says $40 million, but the total was $60 with Amgen providing $20 million on the same terms. A very positive...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.